United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - rasburicase (unii: 08gy9k1euo) (rasburicase - unii:08gy9k1euo) - rasburicase 1.5 mg in 1 ml - elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. limitations of use elitek is indicated only for a single course of treatment [see warnings and precautions (5.1)] . elitek is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase [see boxed warning, warnings and precautions (5.1, 5.2, 5.3)] . elitek is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (g6pd) [see boxed warning, warnings and precautions (5.2)] . risk summary based on findings in animals, elitek may cause fetal harm when administered to pregnant women. in animal reproduction studies, intravenous administration of rasburicase to pregnant rabbits during organo

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rasburicase, quantity: 1.5 mg - injection - excipient ingredients: poloxamer; water for injections - rasburicase is indicated for the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rasburicase -

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rasburicase 1.5mg - powder for infusion - 1.5 mg - active: rasburicase 1.5mg excipient: alanine dibasic sodium phosphate dihydrate dibasic sodium phosphate dodecahydrate mannitol monobasic sodium phosphate dihydrate poloxamer 188 water for injection - the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - rasburicase 7.5mg - powder for infusion - 7.5 mg - active: rasburicase 7.5mg excipient: alanine dibasic sodium phosphate dihydrate dibasic sodium phosphate dodecahydrate mannitol monobasic sodium phosphate poloxamer 188 water for injection - the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - rasburicase - hyperuricemia - all other therapeutic products - treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.

Canada - English - Health Canada

sanofi-aventis canada inc - rasburicase - powder for solution - 1.5mg - rasburicase 1.5mg - enzymes

Canada - English - Health Canada

sanofi-aventis canada inc - rasburicase - powder for solution - 7.5mg - rasburicase 7.5mg - enzymes

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - rasburicase - injection, powder, for solution - 1.5 mg/vial - rasburicase 1.5 mg/vial

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - rasburicase - powder and solvent for solution for infusion - 1.5mg